Similar Search Results

Behind the scenes : sources of complementarity in R&D

Ceccagnoli, Marco; Higgins, Matthew J.; Palermo, Vincenzo - 2013

Persistent link: https://www.econbiz.de/10009722826

Evaluation and Learning in R&D Investment

Frankel, Alex; Krieger, Joshua L.; Li, Danielle; … - National Bureau of Economic Research - 2023

We examine the role of spillover learning in shaping the value of exploratory versus incremental R&D. Using data from drug development, we show that novel drug candidates generate more knowledge spillovers than incremental ones. Despite being less likely to reach regulatory approval, they are...

Persistent link: https://www.econbiz.de/10014287391

Can Operation Warp Speed Serve as a Model for Accelerating Innovations Beyond COVID Vaccines?

D'Souza, Arielle; Hoyt, Kendall; Snyder, Christopher M.; … - National Bureau of Economic Research - 2024

Operation Warp Speed (OWS) was a U.S. government-led program to accelerate the development, production, and administration of COVID-19 vaccines. The program cut the typical ten-year timeline needed to develop a new vaccine down to ten months and began vaccinating vulnerable populations within a...

Persistent link: https://www.econbiz.de/10015056157

Improving Regulation for Innovation : Evidence from China's Pharmaceutical Industry

Jia, Ruixue; Ma, Xiao; Yang, Jianan; Zhang, Yiran - National Bureau of Economic Research - 2023

This study investigates how enhanced regulation can promote innovation, focusing on the impacts of a significant … recognized the improvement in drug innovation, as reflected in stock price adjustments post new drug registrations after the … latecomers could boost their innovation potential by adopting specific, effective regulatory practices from frontier countries …

Persistent link: https://www.econbiz.de/10014447297

The revolution re-visited : clinical and genetics research paradigms and the productivity paradox in drug discovery

Gittelman, Michelle - In: Research policy : policy, management and economic … 45 (2016) 8, pp. 1570-1585

Persistent link: https://www.econbiz.de/10011599152

Rushed innovation : evidence from drug licensing

Hermosilla, Manuel - In: Management science : journal of the Institute for … 67 (2021) 1, pp. 257-278

Persistent link: https://www.econbiz.de/10012435267

R&D portfolios and pharmaceutical licensing

Nishimura, Junichi; Okada, Yosuke - In: Research Policy 43 (2014) 7, pp. 1250-1263

between 1997 and 2007. We pay special attention to stage-specific licensing by dividing the innovation process into early and …

Persistent link: https://www.econbiz.de/10010785083

Calculating the Costs and Benefits of Advance Preparations for Future Pandemics

Glennerster, Rachel; Snyder, Christopher M.; Tan, … - National Bureau of Economic Research - 2022

The Covid-19 pandemic is estimated to have caused over 7 million deaths and reduced economic output by over $13 trillion to date. While vaccines were developed and deployed with unprecedented speed, pre-pandemic investments could have accelerated their widespread introduction, saving millions of...

Persistent link: https://www.econbiz.de/10013435127

Inefficiencies in technology transfer: theory and empirics

Allain, Marie-Laure; Henry, Emeric; Kyle, Margaret K - C.E.P.R. Discussion Papers - 2011

Markets for technology can promote innovation by allowing for division of labor in research and development. Some firms …

Persistent link: https://www.econbiz.de/10008854505

One lab, two firms, many possibilities : on R&D outsourcing in the biopharmaceutical industry

Billette de Villemeur, Étienne; Versaevel, Bruno - In: Journal of health economics 65 (2019), pp. 260-283

Persistent link: https://www.econbiz.de/10012224616